TX-MCKESSON
7.7.2021 14:02:10 CEST | Business Wire | Press release
McKesson Corporation (NYSE: MCK) today announced that it has entered into an agreement to sell its European businesses in France, Italy, Ireland, Portugal, Belgium, and Slovenia to the PHOENIX group. This transaction also includes McKesson’s German-based AG headquarters in Stuttgart, Recucare GmbH, its German wound-care business, its shared services center in Lithuania, and its 45% ownership stake in Brocacef, the company’s joint venture in the Netherlands. The transaction is expected to close in 2022, subject to customary closing conditions, including receipt of required regulatory approvals.
The remaining European businesses in the UK, Norway, Austria, and Denmark are not included in this transaction and will continue to be operated by McKesson. However, McKesson is committed to exploring strategic alternatives for all remaining European businesses and focusing future investments on growth strategies outside of Europe. McKesson will also retain its minority equity stake in the company’s Germany joint venture with Walgreens Boots Alliance.
“Today’s transaction marks an important step in advancing McKesson’s commitment to streamline the business and prioritize investments in the areas where we have deep expertise and are central to our long-term growth strategy,” said Brian Tyler, chief executive officer, McKesson. “We are confident that under the PHOENIX group’s strong leadership, the businesses included in this agreement will be well-positioned for the future to compete more effectively and better serve customers. We will continue to operate our remaining businesses in the UK, Norway, Austria, and Denmark while also exploring a strategic path forward to fully exit the European region. Our goal is to accelerate our growth strategies, becoming a more focused organization and enabling our mission to improve care in every setting.”
The PHOENIX group is a leading integrated healthcare provider and a leader in the European healthcare sector, with over 25 years’ experience serving customers, patients, and partners across Europe. The PHOENIX group shares McKesson’s deep commitment to these groups, which is one of the many reasons that the PHOENIX group is the ideal leader to take these European businesses into the future.
As previously announced, McKesson will release its first quarter fiscal 2022 financial results after market close on Wednesday, August 4, 2021. The Company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The Company will not provide further comments regarding the sale of the European businesses until its earnings call on August 4, 2021.
Cautionary Statements
Except for historical information, statements in this press release elated to McKesson’s proposed disposition of certain operations and assets in Europe constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we might be adversely impacted by delays or other difficulties with divestitures such as the transactions described in this press release; we from time to time record significant charges from impairment to goodwill, intangibles and other assets or investments; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events.
About McKesson Corporation
McKesson Corporation is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information solutions. McKesson partners with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare to help provide the right medicines, medical products and healthcare services to the right patients at the right time, safely and cost-effectively. United by our ICARE shared principles, our employees work every day to innovate and deliver opportunities that make our customers and partners more successful – all for the better health of patients. McKesson has been named a “Most Admired Company ” in the healthcare wholesaler category by FORTUNE, a “Best Place to Work ” by the Human Rights Campaign Foundation, and a top military-friendly company by Military Friendly. For more information, visit www.mckesson.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210707005500/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carta Launches Unified Fund of Funds Solution to Automate LP Workflows and Portfolio Visibility24.3.2026 11:01:00 CET | Press release
New AI-powered offering closes the gap between investment data and investor reporting, bringing institutional-grade automation to complex Fund of Funds structures Carta, the world’s first fully interconnected system for private capital, today announced its solution for Fund of Funds, a new offering designed to help managers automate LP reporting, eliminate manual document processing, and gain clearer visibility into their underlying portfolio exposure. The product expands a critical link in Carta’s ERP for private capital, bringing LP investment data, fund accounting, and portfolio analytics onto a single platform, while more deeply connecting allocators with the GP ecosystem. Fund of Funds represents a critical and growing segment of the private capital ecosystem, projected to reach $450 billion by 2033 as investors seek diversified exposure to private markets. Yet, operating a fund of funds remains highly complex. Managers sit at a unique intersection of the ecosystem, investing as L
Meeting Rising AI Expectations and Removing Friction Key to Meeting Needs of B2B Buyers Across Europe24.3.2026 11:00:00 CET | Press release
8 in 10 buyers use AI in payments, but strategic integration remains uneven and caution abounds in France and GermanyPay by invoice, a core European expectation, a major growth lever in 2026, but payment preferences vary by country and company size According to a new European study1 of 550 business buyers commissioned by TreviPay, the global B2B payments invoicing and payments network, friction in the B2B buying process in the form of slow onboarding and inconsistent invoicing along with rising expectations for AI-enabled processes are where businesses are experiencing threats to loyalty beyond price. “Across Europe and the UK, finance teams are navigating economic pressure, regulatory complexity and rising buyer expectations,” said Inez Berkhof-Hollander, TreviPay’s Vice President of EMEA. “Our research shows payment and invoicing experiences now play a decisive role in supplier selection.” Top Three European Market Expectations in 2026 1. More AI-driven purchasing options vary by cou
OCTO and Volkswagen Group Info Services AG Form Partnership for Fleet Data Integration24.3.2026 10:00:00 CET | Press release
The partnership enables secure integration of vehicle data from six Volkswagen Group brands into OCTO’s platform, strengthening fleet data services across the European Union and supporting utilization, maintenance and geo-location use cases without additional hardware. OCTO, a leading company in the field of telematics, data analytics and AI-driven solutions for insurance and fleet management, announces a strategic partnership with Volkswagen Group Info Services AG. The goal of this cooperation is to expand data solutions for fleet operators by directly integrating vehicle data from the brands Volkswagen Passenger Cars, Volkswagen Commercial Vehicles, Škoda, Seat, Cupra and Audi. Through this partnership, OCTO gains direct access to vehicle data from fleet vehicles of these six Volkswagen brands. This enables innovative mobility services for fleet managers, including maintenance management, theft protection, damage management, fraud detection, driving behavior analysis, activity report
Wolters Kluwer-undersøgelse: Danske SMV'er er førende i Europa inden for AI-drevet omkostningsbesparelser24.3.2026 10:00:00 CET | Pressemeddelelse
Høj reguleringsparathed og pragmatisk teknologiimplementering hjælper virksomheder med at skabe afkast, selvom finansieringsbegrænsningerne vokser Wolters Kluwer Tax & Accounting har i dag offentliggjort sin første rapport Future Ready Businessder viser, at danske små og mellemstore virksomheder (SMV'er) er de mest tilfredse i Europa med AI-drevet omkostningsbesparelser. Blandt SMV'er, der bruger AI, siger 65 %, at det har overgået forventningerne til omkostningsreduktion, hvilket er det stærkeste resultat på tværs af alle EU-markeder, langt foran lande som Tyskland og Spanien. Undersøgelsens resultater tegner et kontrastfyldt billede af markedet, hvor danske SMV'er kombinerer høj reguleringsparathed og en stærk præference for strategisk outsourcing med et stigende pres fra stigende omkostninger og begrænset adgang til kredit. "AI i Danmark implementeres med et klart forretningsmæssigt formål, ikke som en teknologisk trend," siger Martin Tage, Country Manager, Wolters Kluwer Tax & Acco
Mosaic Therapeutics to Present Poster Highlighting Preclinical Data for Lead Program MOS101 at the American Association for Cancer Research (AACR) Annual Meeting 202624.3.2026 09:30:00 CET | Press release
First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumorsAdditional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced it will hold a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, CA. Poster Presentation Details: Title: "Combination of the MDM2 antagonist ASTX295 and olaparib as a novel treatment option for BRCA2 mutant, TP53 wild-type solid tumors” Abstract Number: 3053 Date and Time: Monday, April 20, 2026, 2:00PM – 5:00PM PST Session Category: Novel Targets and Pathways Session: PO.ET09.09 Location: Poster Section 15 For more information an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom